Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials
There remains uncertainty regarding the optimal second-line chemotherapy in advanced pancreatic ductal adenocarcinoma (PDAC). The current recommendation of 5-fluorouracil and oxaliplatin may not be relevant in current practice, as FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan and oxaliplatin) has become a more popular first line therapy in fit patients. The majority of studies in this setting are single-arm Phase II trials with significant heterogeneity of patient populations, treatments and outcomes. In this review, we sought to systematically review and synthesise all prospective data available for the second-line treatment of advanced PDAC.
|ISBN||1879-0461 (Electronic) 1040-8428 (Linking)|
|Authors||Nagrial, A. M.; Chin, V. T.; Sjoquist, K. M.; Pajic, M.; Horvath, L. G.; Biankin, A. V.; Yip, D.;|
|Responsible Garvan Author|
|Publisher Name||CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY|
|URL link to publisher's version||http://www.ncbi.nlm.nih.gov/pubmed/26481952|
|OpenAccess link to author's accepted manuscript version||https://publications.gimr.garvan.org.au/open-access/13240|